Lycia Therapeutics, Inc. (LYCA) shareholders
Close on Nov 18, 2026Market cap –P/E –Yield –
Ownership
Who owns Lycia Therapeutics's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. Joint filing with VHCP Co-Investment Holdings III, LLC (11.90%), Venrock Healthcare Capital Partners EG, L.P. (11.90%) and 6 more | 6,850,237 | 11.90% | 13G (passive) | Oct 23, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Aetna Wun Trombley | President and CEO, Director, 10% owner | 415,255 | Oct 26, 2026 |
| Steven Staben | Chief Scientific Officer, 10% owner | 55,448 | Oct 26, 2026 |
| Amy Bachrodt | Chief Financial Officer, 10% owner | – | Oct 26, 2026 |
| Chin Hyok Lee | Chief Medical Officer, 10% owner | – | Oct 26, 2026 |
| Sofia Touami | Chief Business Officer | – | Oct 26, 2026 |
| William Jl Rieflin | Director | 89,781 | Oct 26, 2026 |
| Jane Henderson | Director | – | Oct 26, 2026 |
| Laurent Fischer | Director | 33,269 | Oct 26, 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 10% owner | 6,858,542 | Nov 4, 2026 |
| VHCP Management EG, LLC | 10% owner | – | Nov 4, 2026 |
| Venrock Healthcare Capital Partners EG, L.P. | 10% owner | – | Nov 4, 2026 |
| VHCP Co-Investment Holdings III, LLC | 10% owner | – | Nov 4, 2026 |
| Venrock Healthcare Capital Partners XP, L.P. | 10% owner | – | Nov 4, 2026 |
| VHCP Management XP, LLC | 10% owner | – | Nov 4, 2026 |
| VHCP Management III, LLC | 10% owner | – | Nov 4, 2026 |
| Bong Y. Koh | 10% owner | – | Nov 4, 2026 |
| Nimish P. Shah | 10% owner | – | Nov 4, 2026 |
| Versant Ventures VII GP, L.P. | 10% owner | 1,393,882 | Oct 28, 2026 |
| Versant Vantage II GP, L.P. | 10% owner | – | Oct 28, 2026 |
| Versant Vantage II GP-GP, LLC | 10% owner | – | Oct 28, 2026 |
| Versant Venture Capital VII, L.P. | 10% owner | – | Oct 28, 2026 |
| Versant Vantage II, L.P. | 10% owner | – | Oct 28, 2026 |
| Versant Ventures VII GP-GP, LLC | 10% owner | – | Oct 28, 2026 |
| LILLY & Co ELI | 10% owner | 1,104,558 | Oct 22, 2026 |
| Carolyn R. Bertozzi | 10% owner | 904,821 | Oct 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Nov 2, 2026 | Buy | +8,305 | $26.95 | $223.82K | 6,858,542 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Oct 30, 2026 | Buy | +200 | $26.86 | $5.37K | 6,850,237 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Oct 30, 2026 | Buy | +8,804 | $26.27 | $231.28K | 6,850,037 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Oct 29, 2026 | Buy | +1,000 | $26.33 | $26.33K | 6,841,233 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Oct 28, 2026 | Buy | +4,430 | $25.97 | $115.05K | 6,840,233 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Oct 28, 2026 | Buy | +10,570 | $25.23 | $266.68K | 6,835,803 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Oct 27, 2026 | Buy | +31,067 | $26.84 | $833.84K | 6,825,233 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Oct 27, 2026 | Buy | +8,729 | $25.84 | $225.56K | 6,794,166 |
| Versant Ventures VII GP, L.P. 10% owner | Oct 26, 2026 | Conversion | +1,393,882 | – | – | 1,393,882 |
| Versant Ventures VII GP, L.P. 10% owner | Oct 26, 2026 | Conversion | +5,631,425 | – | – | 5,631,425 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Oct 26, 2026 | Buy | +8,261 | $26.97 | $222.80K | 6,785,437 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Oct 26, 2026 | Buy | +1,944,444 | $18.00 | $35.00M | 6,777,176 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Oct 26, 2026 | Conversion | +4,779,793 | – | – | 4,832,732 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Oct 23, 2026 | Buy | +28,379 | $26.11 | $740.98K | 52,939 |
| Venrock Healthcare Capital Partners III, L.P. 10% owner | Oct 23, 2026 | Buy | +24,560 | $25.68 | $630.70K | 24,560 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Lycia Therapeutics's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
See a number that looks wrong?